Key points are not available for this paper at this time.
Thalidomide (N‐phthaloylglutamimide) was administered to 21 patients with fourteen types of cancer for periods of 1 to 34 weeks, with total doses ranging from 4.2 to 354.0 Gm. There were mild hemologic and neurological untoward effects. Notumor regression was noted but there was significant subjective palliation in 7 patients. Further study of this drug in patients with advanced cancer is warranted. Palliation was noted to be chiefly improved sedation in disturbed and elderly persons. There was possible arrest of previously rapid growth of tumor in 2 cases.
Olson et al. (Sat,) studied this question.